280 related articles for article (PubMed ID: 18725288)
1. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).
Sim HM; Lee CY; Ee PL; Go ML
Eur J Pharm Sci; 2008 Nov; 35(4):293-306. PubMed ID: 18725288
[TBL] [Abstract][Full Text] [Related]
2. Aurones as modulators of ABCG2 and ABCB1: synthesis and structure-activity relationships.
Sim HM; Loh KY; Yeo WK; Lee CY; Go ML
ChemMedChem; 2011 Apr; 6(4):713-24. PubMed ID: 21302361
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
4. Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues.
Han Y; Riwanto M; Go ML; Ee PL
Eur J Pharm Sci; 2008 Sep; 35(1-2):30-41. PubMed ID: 18598762
[TBL] [Abstract][Full Text] [Related]
5. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
6. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
[TBL] [Abstract][Full Text] [Related]
7. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
10. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein.
Liu XL; Tee HW; Go ML
Bioorg Med Chem; 2008 Jan; 16(1):171-80. PubMed ID: 17964170
[TBL] [Abstract][Full Text] [Related]
11. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.
Valdameri G; Pereira Rangel L; Spatafora C; Guitton J; Gauthier C; Arnaud O; Ferreira-Pereira A; Falson P; Winnischofer SM; Rocha ME; Tringali C; Di Pietro A
ACS Chem Biol; 2012 Feb; 7(2):322-30. PubMed ID: 22039929
[TBL] [Abstract][Full Text] [Related]
12. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
Juvale K; Pape VF; Wiese M
Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
[TBL] [Abstract][Full Text] [Related]
13. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
14. Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
Gozzi GJ; Bouaziz Z; Winter E; Daflon-Yunes N; Honorat M; Guragossian N; Marminon C; Valdameri G; Bollacke A; Guillon J; Pinaud N; Marchivie M; Cadena SM; Jose J; Le Borgne M; Di Pietro A
Drug Des Devel Ther; 2015; 9():3481-95. PubMed ID: 26170632
[TBL] [Abstract][Full Text] [Related]
15. Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
Jabor Gozzi G; Bouaziz Z; Winter E; Daflon-Yunes N; Aichele D; Nacereddine A; Marminon C; Valdameri G; Zeinyeh W; Bollacke A; Guillon J; Lacoudre A; Pinaud N; Cadena SM; Jose J; Le Borgne M; Di Pietro A
J Med Chem; 2015 Jan; 58(1):265-77. PubMed ID: 25272055
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs.
Sim HM; Wu CP; Ambudkar SV; Go ML
Biochem Pharmacol; 2011 Dec; 82(11):1562-71. PubMed ID: 21855533
[TBL] [Abstract][Full Text] [Related]
17. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
[TBL] [Abstract][Full Text] [Related]
18. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
19. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
20. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Poller B; Wagenaar E; Tang SC; Schinkel AH
Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]